124.3 🩺 內科專科考前版

📖 䞭文抂念說明專科版額倖芁熟悉的是 22e 新增的 sepsis biomarkers (monocyte HLA-DR / MR-proADM)、rapid diagnostics (BioFire multiplex PCR / MALDI-TOF / T2 Bacteria-Candida)、AI-based predictor (TREWS, NEWS-2)以及台灣 ASP 制床與 source control timing。Source control 是專科會考的隱藏題 — 埀埀圚 case 題裡考「為什麌抗生玠打了 48 小時還沒退燒」答案垞垞是 source 沒處理 (abscess 沒匕、infected line 沒拔、necrotic tissue 沒 debride)。蚘䜏臚床原則Source control 6-12 小時內 是 sepsis 的 ideal timing越拖死亡率越高。

124.3.0.1 📌 Specialist Pearls

  • Surviving Sepsis Campaign 2021: 1-hr bundle (侊)
  • Antimicrobial stewardship: PCT-guided de-escalation 瞮短 antibiotic 䜿甚
  • Source control: drain, debride, remove infected foreign body — 䞍可省
  • Diagnostic stewardship: 䞍必芁的 test (urinalysis on asymptomatic) → false + → 過床 treat

124.3.0.2 1⃣ 22E 曎新

  • Procalcitonin (PCT): bacterial 區分 + 䜿甚远蹀PCT trend ↓ → de-escalate
  • CRP + PCT 䞍可單獚刀定; 結合 clinical
  • Sepsis biomarkers (新): monocyte HLA-DR (immunoparalysis), MR-proADM
  • Rapid diagnostics: PCR multiplex (BioFire), MALDI-TOF, T2 (T2 Bacteria, T2 Candida)
  • AI-based: TREWS / NEWS-2 預枬 sepsis

124.3.0.3 2⃣ Antimicrobial Stewardship Programs (ASP) — 台灣 context

  • 健保掚動 antibiotic 䜿甚審栞
  • ID consult mandatory for restricted antibiotics (vanco, carbapenem, daptomycin, polymyxin)
  • 院內 antibiogram → guide empirical
  • De-escalation: 培逊 + sensitivity 出䟆 → narrow spectrum

124.3.0.4 3⃣ Source Control

  • 重芁 — 沒做奜則 antibiotics 倱敗
  • ç¶“å…ž: Abscess drain, infected line removal, foreign body removal, surgical debridement, dialysis-line replacement
  • Timing: < 6-12 hr ideally (sepsis), < 24 hr 普通